Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc- induced apoptosis via INK4a/ARF

Genes and Development

Volumn 13, Issue 20, 1999, Pages 2678-2690

  Jacobs, Jacqueline J L ^a   Scheijen, Blanca ^a   Voncken, Jan Willem ^a   Kieboom, Karin ^a   Berns, Anton ^a   Van Lohuizen, Maarten ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Apoptosis; Bmi 1; c Myc; ink4a ARF; Tumorigenesis

Indexed keywords

LIPOCORTIN 5; ONCOPROTEIN; ONCOPROTEIN BMI 1; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; GENE LOCUS; GENE OVEREXPRESSION; HETEROZYGOSITY; LYMPHOMA; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; REGULATOR GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; COCARCINOGENESIS; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENES, BCL-2; GENES, MYC; GENES, P16; HETEROZYGOTE; LYMPHOMA, B-CELL; MALE; MICE; MICE, KNOCKOUT; MICE, MUTANT STRAINS; NUCLEAR PROTEINS; PROTEINS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0033569429     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.13.20.2678     Document Type: Article

References (55)

1. Akashi, K., M. Kondo, U. von Freeden-Jeffry, R. Murray, and I. Weissman. 1997. Bcl-2 rescues T lymphopoieses in Interleukin-7 receptor-deficient mice. Cell 89: 1033-1041.
2. Alkema, M.J., H. Jacobs, M. van Lohuizen, and A. Berns. 1997. Perturbation of B and T cell development and predisposition to lymphomagenesis in Eμ-Bmi1 transgenic mice require the Bmi1 RING finger. Oncogene 15: 899-910.
3. Assoian, R.K. 1997. Anchorage-dependent cell cycle progression. J. Cell Biol. 136: 1-4.
4. Bissonette, R.P., F. Echeverri, A. Mahboubi, and D.R. Green. 1992. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359: 522-554.
5. Blyth, K., A. Terry, M. O'Hara, E.W. Baxter, M. Campbell, M. Stewart, L.A. Donehower, D.E. Onions, J.C. Neil, and E.R. Cameron. 1995. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas; contrasting effects of homozygous and heterozygous p53 loss. Oncogene 10: 1717-1723.
6. Davis, A.C., M. Wims, G.D. Spotts, S.R. Hann, and A. Bradley. 1993. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes & Dev. 7: 671-682.
7. de Stanchina, E., M.E. McCurrach, F. Zindy, S.-Y. Shieh, G. Ferbeyre, A.V. Samuelson, C. Prives, M.F. Roussel, C.J. Sherr, and S.W. Lowe. 1998. E1A signaling to p53 involves the p19arf tumor suppressor. Genes & Dev. 12: 2434-2442.
8. Eischen, C.M., J.D. Weber, M.F. Roussel, C.J. Sherr, and J.L. Cleveland. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes & Dev. (This paper)
9. Elson, A., C. Deng, J. Campos-Torres, L.A. Donehower, and P. Leder. 1995. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene 11: 181-190.
10. Evan, G. and T. Littlewood. 1998. A matter of life and cell death. Science 281: 1317-1322.
11. Evan, G.I., A.H. Wyllie, C.S. Gilbert, T.D. Littlewood, H. Land, M. Brooks, C.M. Water, L.Z. Penn, and D.C. Hancock. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128.
12. Facchini, L.M. and L.Z. Penn. 1998. The molecular role of Myc in growth and transformation: Recent discoveries lead to new insights. FASEB J. 12: 633-651.
13. Fanidi, A., E.A. Harrington, and G.I. Evan. 1992. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359: 554-556.
14. Felsher, D.W. and J.M. Bishop. 1999. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. 96: 3940-3944.
15. Harris, A.W., C.A. Pinkert, M. Crawford, W.Y. Langdon, R.L. Brinster, and J.M. Adams. 1988. The Eμ-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med. 167: 353-371.
16. Haupt, Y., W.S. Alexander, G. Barri, S.P. Klinken, and J.M. Adams. 1991. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Ep-myc transgenic mice. Cell 65: 753-763.
17. Haupt, Y., M.L. Bath, A.W. Harris, and J.M. Adams. 1993. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene 8: 3161-3164.
18. Henriksson, M. and B. Luscher. 1996. Proteins of the Myc network: Essential regulators of cell growth and differentiation. Adv. Cancer Res. 68: 109-182.
19. Hermeking, H. and D. Eick. 1994. Mediation of c-myc-induced apoptosis by p53. Science 265: 2091-2093.
20. Hsu, B., M.C. Marin, A.K. El-Naggar, L.C. Stephens, S. Brisbay, and T.J. McDonnel. 1995. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene 11: 175-179.
21. Hueber, A.-O., M. Zörnig, D. Lyon, T. Suda, S. Nagata, and G.I. Evan. 1997. Requirement for the CD95 receptor-ligand pathway in c-Myc induced apoptosis. Science 278: 1305-1309.
22. Jacobs, J.J.L. and M. van Lohuizen. 1999. Cellular memory of transcriptional states by Polycomb-group proteins. Sem. Cell Dev. Biol. 10: 227-235.
23. Jacobs, J.J.L., K. Kieboom, S. Marino, R.A. DePinho, and M. van Lohuizen. 1999. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164-168.
24. Jaenisch, R., H. Fan, and B. Croker. 1975. Infection of preimplantation mouse embryos and of newborn mice with leukemia virus: Tissue distribution of viral DNA and RNA and leukemogenesis in the adult animal. Proc. Natl. Acad. Sci. 72: 4008-4012.
25. Kamijo, T., F. Zindy, M.F. Roussel, D.E. Quelle, J.R. Downing, R.A. Ashmun, G. Grosveld, and C.J. Sherr. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19arf. Cell 91: 641-659.
26. Kauffman-Zeh, A., P. Rodriguez-Viciana, E. Ulrich, C. Gilbert, P. Coffer, J. Downward, and G. Evan. 1997. Nature 385: 544-548.
27. Land, H., L.F. Parada, and R.A. Weinberg. 1983. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncigenes. Nature 304: 596-602.
28. Langdon, W.Y., A.W. Harris, S. Cory, and J. Adams. 1986. The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice. Cell 47: 11-18.
29. Littlewood, T.D., D.C. Hancock, P.S. Danielian, M.G. Parker, and G.I. Evan. 1995. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23: 1686-1690.
30. -/- mice. Cell 89: 1011-1019.
31. McCormack, S.J., Z. Weaver, S. Deming., G. Natarajan, J. Torri, M.D. Johnson, M. Livanage, T. Ried, and R.B. Dickson. 1998. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene 16: 2755-2766.
32. McDonnell, T.J., G. Nunez, F.M. Platt, D. Hockenberry, L London, J.P. McKearn, and S.J. Korsmeyer. 1990. Deregulated Bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mol. Cell. Biol. 10: 1901-1907.
33. McGill, G., A. Shimamura, R.C. Bates, R.E. Savage, and D.E. Fisher. 1997. Loss of matrix adhesion triggers rapid transformation-selective apoptosis in fibroblasts. J. Cell. Biol. 138: 901-911.
34. Nesbit, C.E., J.M. Tersak, and E.V. Prochownik. 1999. Myc oncogenes and human neoplastic disease. Oncogene 18: 3004-3016.
35. arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
36. Prasad, V.S., R.E. LaFond, M. Zhou, K.A. Jacobsen, D.G. Osmond, and C.L. Sidman. 1997. Upregulation of endogenous p53 and induction of in vivo apoptosis in B-lineage lymphomas of Ep-myc transgenic mice by deregulated c-myc transgene. Mol. Carcinogen. 18: 66-77.
37. Prendergast, G.C. 1999. Mechanisms of apoptosis by c-Myc. Oncogene 18: 2967-2987.
38. Rowan, S., R.L. Ludwig, Y. Haupt, S. Bates, X. Lu, M. Oren, and K.H. Vousden. 1996. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J. 15: 827-838.
39. Ruas, M. and G. Peters. 1998. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta. 1378: F115-F177.
40. Sakamuro, D., V. Eviner, K. Elliott, L. Showe, W. White, and G.C. Prendergast. 1995. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene 11: 2411-2418.
41. Serrano, M., G.J. Hannon, and D. Beach. 1993. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
42. Serrano, M., H.-W. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R.A. DePinho. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37.
43. Sharpless, N.E. and R.A. DePinho. 1999. The INK4A/ARF locus and its two gene products. Curt. Opin. Genet. Dev. 9: 22-30.
44. Sherr, C.J. 1998. Tumor surveillance via the ARF-p53 pathway. Genes & Dev. 12: 2984-2991.
45. Strasser, A., A.W. Harris, M.L. Bath, and S. Cory. 1990a. Novel primitive lymphoid tumors induced in transgenic mice by cooperation between myc and bcl2. Nature 348: 331-333.
46. Strasser, A., A.W. Harris, D.L. Vaux, E. Webb, M.L. Bath, J.M. Adams, and S. Cory. 1990b. Abnormalities of the immune system induced by dysregulated bcl-2 expression in transgenic mice. Curr. Topics Microbiol. Immun. 166: 175-181.
47. van der Lugt, N.M.T., J. Domen, K. Linders, M. van Roon, E. Robanus-Maandag, H. te Riele, M. van der Valk, J. Deschamps., M. Sofroniew, M. van Lohuizen et al. 1994. Posterior transformation, neurological abnormalities, and severe hematopoeitic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes & Dev. 8: 757-769.
48. van lohuizen, M. 1998. Functional analysis of mouse Polycomb group genes. Cell. Mol. Life Sci. 54: 71-79.
49. _. 1999. The trithorax-group and Polycomb-group chromatin modifiers: Implications for disease. Curr. Opin. Genet. Dev. 9: 355-361.
50. van Lohuizen, M., S. Verbeek, B. Scheijen, E. Wientjens, H. van der Gulden, and A. Berns. 1991. Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging. Cell 65: 737-752.
51. Verbeek, S., M. van Lohuizen, M. van der Valk, J. Domen, G. Kraal, and A. Berns. 1991. Mice bearing the Eμ-myc and Eμ-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol. Cell. Biol. 11: 1176-1179.
52. Wagner, A.J., J.M. Kokonitis, and N. Hay. 1994. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21 waf1/cip1. Genes & Dev. 8: 2817-2830.
53. Weber, J.D., L.J. Taylor, M.F. Roussel, C.J. Sherr, and D. Bar-Sagi. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biol. 1: 20-26.
54. Zindy, F., D.E. Quelle, M.F. Roussel, and C.J. Sherr. 1997. Expression of the p16ink4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15: 203-211.
55. Zindy, F., C.M. Eischen, D.H. Randle, T. Kamijo, J.L. Cleveland, C.J. Sherr, and M.F. Roussel. 1998. Myc signalling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes & Dev. 12: 2424-2433.